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A B S T R A C T
The brain can be considered a network, existing of multiple interconnected areas with various functions. MRI
provides opportunities to map the large-scale network organization of the brain. We tap into the neurobio-
chemical dimension of these networks, as neuronal functioning and signal traﬃcking across distributed brain
regions relies on the release and presence of neurotransmitters. Using high-ﬁeld MR spectroscopic imaging at
7.0 T, we obtained a non-invasive snapshot of the spatial distribution of the neurotransmitters GABA and glu-
tamate, and investigated interregional associations of these neurotransmitters. We demonstrate that inter-
regional correlations of glutamate and GABA concentrations can be conceptualized as networks. Furthermore,
patients with epilepsy display an increased number of glutamate and GABA connections and increased average
strength of the GABA network. The increased glutamate and GABA connectivity in epilepsy might indicate a
disrupted neurotransmitter balance. In addition to epilepsy, the ‘neurotransmitter networks’ concept might also
provide new insights for other neurological diseases.
1. Introduction
The brain can be considered a network, existing of multiple inter-
connected brain areas with various functions (van Straaten, 2012).
Several studies have shown that measures of connectivity between
these areas can be associated with cognitive functions (Song et al.,
2008; van den Heuvel et al., 2009), and that the connections are af-
fected in several neurological diseases (Fox and Greicius, 2010;
Spencer, 2002). Characterization of brain networks gained large in-
terest in both neuroscience and neurological studies and diﬀerent
methods are currently being employed. First of all, methods such as
functional MRI and EEG can be applied to assess the so-called ‘func-
tional networks’: areas are linked together and characterized based on
simultaneous brain activity. Other methods characterize brain networks
based on structural connectivity, by employing diﬀusion MRI, thereby
visualizing ﬁber bundles in the brain (Jones, 2008), or over individuals
assessing shared distributions of cortical thickness (He et al., 2007).
One particular disease that is often studied using network theory is
localization-related epilepsy (i.e. epilepsy with a presumed focal
structural cause that cannot be identiﬁed historically or be seen with
current imaging techniques). Although traditionally considered a focal
disease, studies applying functional MRI and diﬀusion MRI have pro-
vided convincing evidence that localization-related epilepsy exhibits
profound alterations in both local and distributed functional and
structural networks (Bernhardt et al., 2013). Proper neuronal func-
tioning and signal traﬃcking across distributed brain regions also rely
on the release and presence of chemical components, in particular
neurotransmitters. Functional and diﬀusion MRI cannot provide direct
information on defective neurons or the associated neurotransmitter
disbalance, which underlies abnormal neuronal activity, an essential
feature of seizures. Insights into the neurotransmitter network dys-
function in localization-related epilepsy might be of great value to
eventually better understand the neuronal network characteristics of
epilepsy and also other brain diseases.
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Proton MR Spectroscopy (1H-MRS) enables the non-invasive detec-
tion and quantiﬁcation of metabolite concentrations in the brain,
thereby oﬀering a window on brain cell metabolism (Rae, 2014). Tra-
ditionally, neurometabolites such as N-acetyl-aspartate (NAA; surrogate
marker of neuronal density, primarily localized in the central and
peripheral nervous system) and creatine (Cr; involved in energy meta-
bolism, often regarded as suitable in vivo concentration reference) are
being measured. Aberrant levels of these neurometabolites have been
found in epilepsy, but also other neurological diseases or in aging (Öz
et al., 2014; Petroﬀ, 2005). More advanced studies also focus on mea-
surements of the inhibitory and excitatory neurotransmitters GABA and
glutamate, which can be associated with neural activity (Duncan et al.,
2014). However, these studies traditionally consider only local meta-
bolite concentrations, while healthy brain functioning does not only
rely on individual brain areas, but also requires proper signal traf-
ﬁcking, and thus relations between distant brain areas (Park and
Friston, 2013). Using high-ﬁeld 1H-MRS imaging at 7.0 T, it is possible
to obtain a snapshot of the spatial distribution of GABA and glutamate
with a high (mL) spatial resolution.
Therefore, the concept of ‘neurotransmitter networks’ is introduced
in this study. This new method relates to the assessment of coordinated
spatial variations in neurotransmitter concentrations in the brain across
individuals, and might be able to provide additional information on the
underlying metabolic changes which aﬀect neuronal functions. We
primarily focussed on glutamate and GABA, due to their roles as im-
portant excitatory and inhibitory neurotransmitters in the brain.
Additionally, NAA networks were considered, as NAA is the neurome-
tabolite that is easiest to measure, although not directly involved in
signaling. We assessed the construction and ﬁrst applicability of ‘neu-
rotransmitter networks’. The concept is ﬁrst applied healthy partici-
pants, and subsequently compared between patients with epilepsy and
healthy participants.
2. Materials and methods
2.1. Study procedures
Two groups of participants, healthy volunteers and patients with
epilepsy, were included. The exclusion criteria for both groups were all
contraindications for MR scanning (such as metal implants or preg-
nancy), and a medical history with (other) neurological diseases.
Additional exclusion criteria for the patients with epilepsy were MRI
visible lesions (seen on clinical 3 T scans), changes in antiepileptic
drugs (medication or dose) in the last twelve months, or a seizure fre-
quency higher than once a month.
All participants provided written informed consent before partici-
pation. Ethical approval for this study was obtained from the medical
ethical committee academic hospital Maastricht/Maastricht University,
and the study was registered at the Dutch Trial Register with registra-
tion number NTR4878.
Each participant underwent a 7 Tesla MR examination (Magnetom,
Siemens Healthineers, Erlangen, Germany) with a 32-channel head coil.
The scanning procedure included whole brain T1-weighted imaging
(MP2RAGE (Marques et al., 2010), TR/TE 4500/2.39ms, TI1/TI2 900/
2750ms, FOV 173×230×230mm3, cubic voxel size
0.9×0.9×0.9mm3), a whole brain ﬂuid attenuation inversion re-
covery (FLAIR) sequence (TR/TE 8000/303ms, TI 2330ms, FOV
166.4× 224×256mm3, cubic voxel size 0.8× 0.8× 0.8mm3), and
an MRSI acquisition. For the latter, a semi-LASER sequence was ap-
plied, which combines conventional RF pulses for slice excitation with
orthogonal adiabatic refocusing pulses for volume selection (Scheenen
et al., 2008). Frequency oﬀset corrected inversion (cFOCI) pulses were
included in this sequence to limit chemical shift artifacts (Ordidge et al.,
1996). Other parameters were TR/TE 5520/38ms, VAPOR water sup-
pression, FOV 150×150×100mm3 (Fig. 1), and voxel size
9.4×9.4×12.5 mm3 (1.1mL).
Five of the healthy controls were scanned twice, with a seven-day
interval, to assess the inter-scan reproducibility of the MRSI measures.
Both T1-weighted and FLAIR images were checked by a neuroradiolo-
gist (P.A.M.H.) for abnormalities.
2.2. Data analysis
2.2.1. Metabolite concentrations
Before constructing the metabolite networks, the metabolite con-
centrations per brain area were computed. For this purpose, informa-
tion from the anatomical scan and the spectra were preprocessed and
analyzed (Fig. 2). With the MP2RAGE sequence, images were obtained
for two inversion times: TI1 (GRETI1) and TI2 (GRETI2), which were
combined to create a quantitative longitudinal relaxation time T1-
weighted image (Marques et al., 2010). The GRETI2 scan was skull
stripped using the brain extraction tool (BET) of FMRIB Software Li-
brary (FSL, version 5.0.1) (Jenkinson et al., 2012; Smith, 2002). The T1
map was segmented in grey matter, white matter, and cerebrospinal
ﬂuid with FAST, part of FSL (Zhang et al., 2001).
To parcellate the brain into a number of standard areas, the atlas
was transformed to the skull stripped T1-weighted image (Fig. 2). The
atlas was deﬁned by thirty non-overlapping brain areas (Table 1) and
was created in MNI space, by combining information from the Harvard-
Oxford cortical and subcortical atlases and the ICBM 2009c nonlinear
symmetric template (Desikan et al., 2006; Fonov et al., 2009; Frazier
et al., 2005). In addition to GM, also WM regions are included, as recent
developments in the ﬁeld indicate that WM has other functions than
pure neuron-to-neuron communication (Butt et al., 2014). Furthermore,
the presence of neurotransmitters is not only related to neuronal sig-
naling or local synaptic activity. It has for example been shown that
neurotransmitters released from axons during action potential propa-
gation acting on glial receptors regulate the homeostatic functions of
astrocytes and myelination by oligodendrocytes. Astrocytes also release
neurotransmitters, maintaining signaling along potentially long axon
tracts. The co-existence of multiple neurotransmitters in the WM are
indicative of diverse functions important for information processing.
The skull stripped T1 maps were non-linearly transformed to the MNI
brain using FNIRT (FSL, version 5.0.1) (Andersson et al., 2007;
Jenkinson et al., 2002; Jenkinson and Smith, 2001). The inverse non-
linear transformation was then applied to transform an atlas to each
individual brain.
Metabolite spectra were analyzed using LCModel (version 6.3,
Fig. 1) with a simulated basis set of 20 metabolites. The 20 model
spectra (Appendix A) of acetate (Ace), ascorbate/vitamin C (Asc), as-
partate (Asp), Cr, GABA, glycine (Gly), glutamate (Glu), glutamine
(Gln), glutathione (GSH), glycerophosphocholine (GPC), myo-inositol
(Ins), NAA, Nacetylaspartylglutamate (NAAG), phosphocholine (PCh),
phosphocreatine (PCr), phosphoethanolamine (PE), taurine (Tau),
scyllo-inositol (Sci), macromolecule 2.0 ppm (MM20), and the correc-
tion term for Cr (eCrCH2) were generated using VESPA (Versatile Si-
mulation, Pulses and Analysis package, (Soher et al., 2011)). Which
applies previously reported chemical shifts and coupling constants in-
itially published by (Govindaraju et al., 2000), which were later up-
dated (Govind et al., 2015), and reﬁned by others including (Kreis and
Bolliger, 2012; Tkac, 2008). Spectra were generated using Lorentzian
lines, 1 Hz broadened, 4 kHz bandwidth, and 2048 points. Veriﬁcation
of the basis set included phantom experiments with varying con-
centrations of GABA and glutamate and visual inspection of spectra. A
macromolecule spectrum acquired with a sLASER sequence
(TE=36ms) at 7 T was initially added to the basis set, but not included
in the ﬁnal analysis after visual inspection. Lipids and other macro-
molecules were estimated using the spline function in LCModel.
Voxelwise spectra were excluded when the signal-to-noise ratio
(SNR) was below 20, the Cramér-Rao lower bounds (CRLBs) of the N-
acetylaspartate plus N-acetylaspartylglutamate concentrations (tNAA)
was higher than 3, the CRLB of creatine plus phosphocreatine (tCr) was
T.M. van Veenendaal et al. NeuroImage: Clinical 19 (2018) 47–55
48
22.533.54
resonance frequency (ppm)
spectrum
fit
individual fits
residual
NAA
GABA (x5)
Glu
A B
Fig. 1. A. Field-of-view of the MRSI image. B. Typical example of a measured spectrum with the quantitative (LCModel) ﬁt, and individual glutamate (glu), GABA and
N-acetylaspartate (NAA) ﬁts.
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Fig. 2. Analysis of the metabolite networks. The spectra were ﬁrst analyzed in LCModel (A) and aligned with the structural image (B), and mean metabolite
concentrations were calculated per area (C). Connections between areas were deﬁned as correlated neurometabolite concentrations (D). Glu: standardized glutamate
concentration; RCG: right cingulate gyrus; LCG: left cingulate gyrus; ROGM: right occipital grey matter.
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higher than 10, or the CRLB of GABA or glutamate was higher than 20.
SNR was deﬁned as the ratio of the maximum in the spectrum-minus-
Baseline over the Analysis Window to twice the root mean square
Residuals (Provencher, 2014). These quality criteria were derived using
an extensive iterative process, in which we evaluated many options to
obtain the best criteria for selection and rejection of spectra. Line width
was not included in these criteria, due to its close interrelationship with
SNR and CRLB (Tkac et al., 2009), which are already taken into ac-
count. The spectra were also excluded if the total grey and white matter
fraction of the corresponding voxel was lower than 50%. As we did not
acquire a separate water spectrum due to time restrictions, we did not
have the option to perform the preferred absolute quantiﬁcation
(Jansen et al., 2006). Hence, all concentrations were expressed relative
to the tCr concentration of the corresponding voxel.
Each MRSI voxel ﬁrst aligned with the T1-weighted image, and then
assigned to the predeﬁned atlas area that showed largest overlap with
the voxel. The average concentration per area was corrected for grey
and white matter content, age and sex with linear regression analysis, in
which the metabolite concentrations were used as the dependent vari-
able (across all participants), and the grey/white matter content, age
and sex as independent variables. Grey/white matter content was de-
ﬁned as the fraction of grey matter divided by the grey plus white
matter fraction. The corrected metabolite concentrations were equal to
the residuals of the linear regression analysis (Eq. (1)):
= + ∙
+
+ ∙ + ∙ +β β β βConc GM
GM WM
age sex Conc0 1 2 3 corr (1)
with Conc the measured (i.e. uncorrected) metabolite concentration per
area, Conccorr the corrected metabolite concentration, GM the percen-
tage grey matter and WM the percentage white matter. The Conccorr can
be interpreted as the metabolite concentration corrected for variations
in grey/white matter content, age, and sex over the participants (si-
milar to (He et al., 2007)). The regression coeﬃcients are displayed as
β, which were not used for subsequent analysis.
Due to the relatively strong intensity inhomogeneities that can be
particularly severe in MRI at ultra-high ﬁeld strengths (e.g. 7 T), it is
common for connectivity analyses to apply a certain bias ﬁeld correc-
tion (Li et al., 2009). Therefore as ﬁnal preprocessing step, standardized
concentrations were calculated over all healthy participants (Eq. (2)):
=
−Conc Conc mean(Conc )
sd(Conc )scaled
corr corr
corr (2)
with Conccorr the corrected and Concscaled the standardized and cor-
rected metabolite concentrations, and sd the standard deviation. To
avoid confusion due to the substantial correction and processing steps,
corrected metabolite concentrations are from now on referred to as
“metabolite indices”.
2.2.2. Brain metabolite networks and measures
A connection between two brain areas was considered present,
when the neurometabolite indices of these two areas correlated sig-
niﬁcantly over the subjects. We assume that areas support concerted
brain activity if an increased neurometabolite concentration in one area
is accompanied with an altered concentration of that neurometabolite
in another area. Areas with correlated neurometabolite indices among
participants are therefore considered ‘metabolically connected’. To
obtain the neurometabolite connectivity matrix, the Pearson's correla-
tion coeﬃcient between the metabolite indices of each pair of areas was
calculated. The weighted connectivity between pairs of areas was equal
to the correlation coeﬃcient ρ if the correlation was below a certain
statistically signiﬁcant threshold (i.e., p < 0.05) and 0 otherwise.
A prerequisite for the analyses is that none of the participants had
areas without good-quality data. Therefore, some areas and participants
were excluded from the ﬁnal analysis (Table 1).
2.2.3. Group comparison
To compare the neurometabolite networks in the patients with
epilepsy with the control-group, two basic network characteristics were
evaluated: the density (i.e. the fraction of actual connections divided by
total number of possible connections), and the average network
strength. The density was calculated in a range of varying thresholds
(varying from ρ=0.1–0.9) for both subject groups. In this comparison,
the Pearson correlation coeﬃcient ρ was applied as threshold, as it is
independent of group size, in contrast with the p-value of a correlation.
For the average network strength, a ﬁxed set of nodes was deﬁned,
which was based on the combined results of the two groups per neu-
rometabolite. The number of connections and the set of possible con-
nections was ﬁxed across the group of individuals (i.e. a ﬁxed network)
to rule out the inﬂuence of network density on the computation and
comparison of graph metrics across groups (van den Heuvel et al.,
2017). The included regions for the ﬁxed analysis can be found in ap-
pendix B. The density of the network was set at 0.2, which corre-
sponded to a threshold of approximately p=0.05 in the healthy sub-
ject-group (Fig. 4A). Subsequently, metabolite networks were created
for patients and controls, using the ﬁxed network, and the connection
strengths of these networks were statistically compared using a bino-
mial test. A consequence of using the covariance method (correlating
over subjects within a group) to construe networks is that only one
network can be obtained per group, preventing the applicability of
traditional Student t-tests. To overcome this problem, we evaluated
whether the entire set of connection strengths of these networks dif-
fered, by evaluating the distribution of connections stronger in patients
and connections stronger in controls, in relationship with the expected
probability based on the total number of connections. For this approach
a binomial test is appropriate (Ansari-Lari, 2004). For this, the number
of connections that were stronger in the patients with epilepsy, and the
number of connections stronger in the healthy participants were tallied.
The probability of this distribution is approximately binomially dis-
tributed, thus the probability of the found distribution can be computed
by:
= − −( )Pr k nk p p( ) (1 )k n k (3)
with k the number of connections that is larger in one group, n the total
number of connections, and p the probability that a single connection is
Table 1
Atlas areas, the number of included spectroscopic voxels per area, and per-
centage of subjects with corresponding data (based on the combined patient
and control group).
Area No. of voxels
(mean ± standard deviation)
Percentage subjects with
good-quality data
Hemisphere Left Right Left Right
Thalamus 4.3 ± 2.1 4.5 ± 1.8 100% 100%
Basal ganglia 4.3 ± 2.7 3.8 ± 2.3 92%a 92%
Hippocampus/
amygdala
1.2 ± 1.2 0.7 ± 0.8 64%a 44%a
Prefrontal GM 13.9 ± 7.3 11.9 ± 6.3 100% 100%
Prefrontal WM 19.8 ± 6.7 20.3 ± 8.0 100% 100%
Insula 7.5 ± 3.8 7.6 ± 4.5 100% 88%a
Premotor GM 6.4 ± 4.8 4.9 ± 4.4 96% 84%a
Premotor WM 11.4 ± 4.7 12.6 ± 4.6 100% 100%
Temporal GM 3.1 ± 3.6 2.1 ± 2.9 68%a 56%a
Temporal WM 11.0 ± 4.9 10.5 ± 6.0 100% 96%b
Parietal GM 12.0 ± 4.7 13.4 ± 5.2 100% 100%
Parietal WM 16.8 ± 4.6 15.4 ± 3.8 100% 100%
Occipital GM 9.4 ± 6.1 10.5 ± 7.7 96%b 92%b
Occipital WM 0.9 ± 1.2 1.0 ± 1.1 48%a 64%a
Cingulate gyrus 5.4 ± 3.1 9.2 ± 2.9 100% 100%
a These areas were excluded in the ﬁnal analyses, because not all participants
had good-quality data in these areas.
b These areas were additionally excluded in the comparison between patients
and healthy participants, because of missing patient data.
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higher in one group than the other (p=0.5).
The p-value is then given by the cumulative distribution:
∑≤ = −
=
−( )Pr x k ni p p( ) (1 )
i
k
i n i
0 (4)
In these analyses, the correction for grey/white matter, age and sex,
and the standardization (as described in Section 2.2.1), was applied
over the pooled group containing both controls and patients.
To test the robustness for within-subject variations, this analysis was
repeated with replacing the data from the 5 healthy participants who
were scanned twice with the ‘second measurements’.
3. Results
3.1. Study population
Thirty participants were included in this study (20 participants
without and 10 with epilepsy). Data of two healthy participants were
excluded because of an overall low spectral quality. Therefore, data of
18 healthy participants (10/8 male/female, age 39.6 ± 16.8 years, age
range: 22–65) were considered for further analyses. All ten patients
with localization-related epilepsy (7/3 male/female, age
40.1 ± 16.5 years, age range: 20–69 years) were included in these
analyses. In none of the participants, epileptogenic abnormalities were
identiﬁed in the 7 T images by our expert neuroradiologist.
3.2. Metabolite concentrations
Concentrations of GABA, glutamate, and NAA were measured in
thirty diﬀerent brain areas (Table 1). No signiﬁcant diﬀerences were
observed for the GABA, glutamate, or NAA concentrations between the
patients and controls in any of these areas (Student's t-test, p > 0.05).
The average SNR per area across all participants was 47 ± 8
(mean ± SD), while the average CRLBs of glutamate, GABA and NAA
were 4.1 ± 0.9, 13.5 ± 0.8, and 2.1 ± 0.2, respectively. The coeﬃ-
cients of variation of the concentration estimates (for the 5 healthy
volunteers who were scanned twice) were 8.4 ± 4.2% for glutamate,
11.4 ± 3.8% for GABA, and 7.8 ± 3.1% for NAA (Appendix C). Fur-
thermore, measured (i.e. uncorrected) concentrations are in the same
range as reported in previous studies, except for GABA, which was
twice as high, possibly due to macromolecule contamination (Appendix
D) (O'Gorman et al., 2011; van Veenendaal et al., 2016). In Appendix E,
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Fig. 3. Correlation matrices of the glutamate (glu), GABA and N-acetylaspartate (NAA) networks in healthy participants. The shape and color of the ovals indicate the
correlations coeﬃcient (ρ) between each pair of areas, i.e. the strength of the connections between those areas and the sign of the correlations (red: negative, blue:
positive). Only connections with a p < 0.05 are displayed. Figures were created in R version 3.2.2 (Team, 2015; Wright, 2016). (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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quantitative data and measures of quality for the Occipital GM are
provided, indicating similar quality for both groups. The glutamate and
NAA concentrations were negatively associated with age in respectively
77% and 73% of the brain areas (linear regression analysis, p < 0.05),
while the GABA concentrations were only negatively associated with
age in 20% of the brain areas (linear regression analysis, p < 0.05). As
no missing data were allowed in the network analyses, data from ﬁfteen
healthy participants and 21 areas were included in these analyses
(Table 1). In case of the analyses in patients, ten patients and eighteen
areas were included.
3.3. Organization of metabolic brain networks
Of the possible connections, 21%, 19%, and 26% showed a sig-
niﬁcant glutamate, GABA, and NAA correlation, respectively,
(p < 0.05) across all ﬁfteen healthy participants (Fig. 3). The density
of the networks is higher than expected purely based on chance (i.e. the
p-value) for all three metabolites (Fig. 4A). The maximum node degree
(number of connections per node) was nine; this was observed in the
left prefrontal white matter (glutamate) or left parietal white matter
(GABA, NAA). All nodes were connected in the glutamate network,
while the GABA network had three unconnected nodes (left and right
prefrontal grey matter, and the right premotor white matter). The NAA
network had two unconnected nodes (left occipital grey matter and
right temporal white matter), and another component (with only two
nodes: right prefrontal white matter and right occipital grey matter)
which was unconnected to the other nodes. The vast majority of con-
nections was positive: no signiﬁcant, negative connections were present
in the glutamate network, while 11% and 4% of the respectively GABA
and NAA connections was negative.
The relation between the number of connections and distance be-
tween the areas is illustrated in Fig. 4B. It can be observed that the
distances between all areas are roughly normally distributed, which is
in close agreement with the distribution of anatomical distances ob-
served for cortical thickness networks (He et al., 2007). The neurome-
tabolite networks include both long- and short distance connections.
3.4. Metabolite networks in epilepsy
The density of the glutamate and GABA networks were higher in the
patients with epilepsy compared with the healthy controls, over a
considerable range of rho thresholds (Fig. 5, Table 2). Also the con-
nection strength of the GABA networks was higher in the patients than
the controls. The average connection strength of the glutamate net-
works was comparable between the patients and controls. The NAA
networks showed a comparable density and node strength in patients
and controls. When comparing the individual connections strengths, the
patients with epilepsy displayed a larger Pearson correlation coeﬃcient
ρ (i.e. strength) compared with the healthy participants in 97 of the 153
glutamate connections (p < 0.001), 103 of the 152 GABA connections
(p < 0.001), and 83 of the 153 NAA connections (p=0.17).
4. Discussion
In this study, the concept of neurotransmitter networks was in-
troduced. A spatial relation between glutamate, GABA, and NAA indices
of diﬀerent areas was shown, suggesting the presence of neurometa-
bolite networks. These networks included both short-range and long-
range connections. Furthermore, some areas were characterized as so-
called “hub areas”: areas with many connections to other areas, while
other areas showed fewer to no connections. Finally, these networks
displayed signiﬁcantly diﬀerent properties in patients with epilepsy in
comparison with healthy participants.
4.1. Interpretation of neurotransmitter networks
An important question is how to interpret these metabolic networks,
or, on a smaller scale, metabolic connections. The conceptual idea is
that areas that are connected, tend to have similar characteristics, an
idea known in social sciences as the “homophily principle” (Simsek and
Jensen, 2008). This principle has previously been applied to neu-
rosciences, for instance in correlated cortical thickness (He et al., 2007),
gene expression in the brain (Richiardi et al., 2015) or serotonin-re-
ceptor binding measured with positron emission tomography (PET)
(Erritzoe et al., 2010).
Although neurotransmitter network correlations should not be
considered as a direct measure of connectivity, it has been shown
previously in cultured hippocampal neurons that synchronous neuronal
ﬁring promotes network-based synaptogenesis (Bi and Poo, 1999). Bi
et al. showed that localized stimulation can modify synapses that are
remote from the stimulated neuron. Changes in polysynaptic pathways
could be accounted for by correlating pre- and postsynaptic excitation
at distant synaptic sites. Hence, anatomical regions that are “con-
nected” might share similar ways of signal traﬃcking that rely on sy-
naptic modiﬁcations. It is currently unknown whether these regions
share a similar receptor architecture or gene expression proﬁle. A
straightforward answer to this question may not be possible, as the
precise relationships among diﬀerent regions of the brain are yet to be
fully characterized. Future studies, combining connectivity measures
from diﬀerent modalities (e.g. functional MRI, diﬀusion MRI, MR
spectroscopy) might provide meaningful insights these relationships.
Additionally, comparisons with quantitative receptor autoradiography,
which can provide regional distribution of neurotransmitter receptors
in the cerebral cortex (Amunts et al., 2010), might provide additional
insights.
Several previous studies already assessed interregional correlations
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in glutamate, GABA, and NAA concentrations (Grachev and Apkarian,
2001; Greenhouse et al., 2016; Kraguljac et al., 2012; Waddell et al.,
2011). It is diﬃcult to compare their results with ours, as they used
diﬀerent methods (e.g. ﬁeld strength, brain areas). Our study showed
the existence of interregional correlations for all three neurometabo-
lites, but the speciﬁc coherence depended on the areas being compared;
not all areas showed a correlation, which might explain the contrasting
results seen in diﬀerent studies.
An explanation for the biological mechanisms behind these con-
nections remains speculative. Beside its function as neurotransmitter,
glutamate is available as metabolic pools in the neuron and linked to
glucose metabolism (Rae, 2014). GABA, on the other hand, is most
likely related to the GABAergic tone (i.e. the level of continuous GA-
BAergic activity, inducing tonic inhibition, which is not necessarily
inhibitory activity) (Rae, 2014). Several studies suggested that neuronal
connectivity is related to GABA- and glutamatergic function. At neu-
ronal level, it has been shown that the probability of a connection be-
tween two types of neurons, correlates with the average synaptic
strength of those two neuron types (Jiang et al., 2015). At brain level,
positive correlations have been shown between glutamate concentra-
tions and functional connectivity, and negative between GABA and
functional connectivity (Duncan et al., 2014).
NAA is considered a surrogate marker for neuronal integrity and
associated with cognitive function (Rae, 2014). It can be hypothesized
that when areas are connected, damage in one brain area is accom-
panied with a decreased neuronal integrity of the other brain area.
Although individual connections are important, these connections
are not isolated, as there is a constant interaction between diﬀerent
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brain areas and their connections. Therefore, it might be beneﬁcial to
assess these brain networks as a whole, which was investigated in this
study. Previous structural and functional studies found that brain net-
works appear so-called “small-world networks”, meaning that they
combine a high integration as well as segregation in the network
(Bullmore and Sporns, 2009). At this moment, such network char-
acteristics could not be assessed, because of the relatively low number
of nodes and the presence of both positive and negative weights, but
this should be explored in further studies.
4.2. Neurotransmitter networks in epilepsy
A higher GABA and glutamate connectivity was shown in patients
with epilepsy compared with a healthy control group, as indicated by
the number of connections and the strengths of the connections. This
increased neurotransmitter connectivity seems to be associated with the
pathophysiology in epilepsy, as epileptic seizures likely disrupt neuro-
transmitter networks. Previous studies showed an increased functional
and structural connectivity in patients around the epileptic zone, but a
decreased connectivity in other brain areas, and it has been suggested
that brain networks are reorganized as a result of recurrent epileptic
seizures (Englot et al., 2016). Also, antiepileptic drugs might alter
glutamate and GABA concentrations (van Veenendaal et al., 2015), and
may result in aberrant metabolic brain networks, but these eﬀects were
beyond the scope of the current study.
Previous studies showed signiﬁcant correlations between NAA
concentrations in the hippocampus, thalamus, and putamen in patients
with temporal lobe epilepsy, while these correlations were absent in
healthy subjects (Hetherington et al., 2007; Pan et al., 2012). No
changes in NAA connectivity were observed in the current study, but
this connectivity might be location-speciﬁc. While these previous stu-
dies studied connectivity between speciﬁc brain areas, we choose to
study overall brain networks.
4.3. Study considerations
This explorative study aimed to introduce the concept of neuro-
transmitter networks and should be considered as proof-of-concept.
Employing a correlation over the group as an outcome measure leads to
some methodological considerations, as it restricts the possibilities for
statistical testing. This was solved by comparing individual connection
strengths between groups. Future, larger studies might adopt statistical
methods applied in cortical thickness studies, that employ similar out-
come measures, such as permutation tests (Bassett et al., 2008; He et al.,
2008) or methods to calculate individual measures (Saggar et al.,
2015). Unfortunately, the group size in this pilot study is not suﬃcient
to employ these methods. Finally, the applied MRSI sequence has some
disadvantages, such as a limited spatial resolution and coverage, and
vulnerability to artifacts. The spatial resolution of our MRSI experiment
is relatively coarse (1.1 mL) in comparison to structural and functional
network experiments, which prompted the use of a brain atlas with
relatively large regions, to ensure a suﬃcient sampling (i.e. suﬃcient
number of overlapping voxels) per region for all subjects. Therefore, the
nodes in the network are relatively large in volume, which ensured that
it was more robust to select the same region over diﬀerent subjects. As
the obtained neurotransmitter networks do show realistic properties
(e.g. both intra and inter-hemispheric connections), we are conﬁdent
regarding the validity of our approach. Some of the disadvantages could
be solved with other sequences, such as GluCEST, which enables whole-
brain glutamate measurements with a high resolution (Cai et al., 2012;
Cai et al., 2013). Future studies with larger group sizes and dedicated
spectroscopic imaging protocols are thus necessary to evaluate the
presented concept in more detail. These future studies might also pro-
vide a better understanding of the concept of a neurotransmitter net-
work. Additionally, in future studies also comparisons with other MRI-
derived networks (e.g. fMRI or DTI based connectivity) could be per-
formed. Lastly, also alternative strategies regarding the MRS analysis,
in terms of quality criteria (Kreis, 2016) and use of simulated basis sets
(Bhogal et al., 2017) should be explored in future studies.
4.4. Future implications
The results are expected to provide a better understanding of the
role of neurotransmitter dysfunction in epilepsy and other neurode-
generative diseases. Non-invasive imaging of neurotransmitter net-
works might provide an early biomarker of patients at risk (i.e. before
the onset of overt symptoms). Lastly, it could aid the development of
novel eﬀective treatment options, and be used to assess the eﬃcacy of
pharmacological interventions.
4.5. Conclusion
This study presents the novel concept of metabolic brain networks
using MR spectroscopic imaging. We showed interregional correlations
of glutamate, GABA, and NAA measurements, which can be con-
ceptualized as networks. We showed the applicability of this concept in
patients with epilepsy; however, it might also provide new insights for
other neurological diseases.
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